In the first episode of a six-part interview series on immunotherapy, Mark Folke, CEO and Executive Director of Immutep (ASX:IMM), discusses the significance and rapid growth of immuno-oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback